Literature DB >> 20230193

The endocannabinoid system as a target for the treatment of neuronal damage.

Javier Fernández-Ruiz1, Concepción García, Onintza Sagredo, María Gómez-Ruiz, Eva de Lago.   

Abstract

IMPORTANCE OF THE FIELD: Cannabinoids have been proposed as clinically promising neuroprotective molecules, based on their capability to normalize glutamate homeostasis, reducing excitotoxicity, to inhibit calcium influx, lowering intracellular levels and the subsequent activation of calcium-dependent destructive pathways, and to reduce the generation of reactive oxygen intermediates or to limit their toxicity, decreasing oxidative injury. Cannabinoids are also able to decrease local inflammatory events by acting on glial processes that regulate neuronal survival, and to restore blood supply by reducing vasocontriction produced by several endothelium-derived factors. AREAS COVERED IN THIS REVIEW: Current literature supporting these neuroprotective effects, particularly evidence generated during the last ten years, concentrating on targets within the cannabinoid signaling system that facilitate these effects. Acute or chronic neurodegenerative disorders where cannabinoids have shown neuroprotective effect. WHAT THE READER WILL GAIN: Most of the information reviewed here relates to preclinical studies. However, these molecules may progress from the present preclinical evidence to clinical applications. TAKE HOME MESSAGE: Treatment of neurodegenerative disorders is a challenge for neuroscientists and neurologists. Unhappily, the efficacy of available medicines is still poor and there is an urgent need for novel neuroprotective agents. Cannabinoids can serve this purpose given their recognized antiexcitotoxic, antioxidant and anti-inflammatory properties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20230193     DOI: 10.1517/14728221003709792

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  32 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

3.  Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro.

Authors:  Emelie Janefjord; Jesper L V Mååg; Benjamin S Harvey; Scott D Smid
Journal:  Cell Mol Neurobiol       Date:  2013-09-13       Impact factor: 5.046

Review 4.  Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.

Authors:  Francisco Espejo-Porras; Fabiana Piscitelli; Roberta Verde; José A Ramos; Vincenzo Di Marzo; Eva de Lago; Javier Fernández-Ruiz
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-29       Impact factor: 4.147

5.  Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.

Authors:  Carmen Rodríguez-Cueto; Cristina Benito; Javier Fernández-Ruiz; Julián Romero; Mariluz Hernández-Gálvez; María Gómez-Ruiz
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

6.  Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Authors:  Karen L G Farizatto; Sara A McEwan; Vinogran Naidoo; Spyros P Nikas; Vidyanand G Shukla; Michael F Almeida; Aaron Byrd; Heather Romine; David A Karanian; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2017-08-12       Impact factor: 3.444

7.  Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Authors:  Sara Valdeolivas; Carmen Navarrete; Irene Cantarero; María L Bellido; Eduardo Muñoz; Onintza Sagredo
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

8.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

9.  Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.

Authors:  O Gomez; A Sanchez-Rodriguez; Mqu Le; C Sanchez-Caro; F Molina-Holgado; E Molina-Holgado
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

10.  A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

Authors:  Jose Luis López-Sendón Moreno; Juan García Caldentey; Patricia Trigo Cubillo; Carolina Ruiz Romero; Guillermo García Ribas; M A Alonso Alonso Arias; María Jesús García de Yébenes; Rosa María Tolón; Ismael Galve-Roperh; Onintza Sagredo; Sara Valdeolivas; Eva Resel; Silvia Ortega-Gutierrez; María Laura García-Bermejo; Javier Fernández Ruiz; Manuel Guzmán; Justo García de Yébenes Prous
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.